{"editorial":{"content_id":"d7ec0098-81c5-4c55-9652-935e4fcf4932","slug":"anvisa-libbs-25d0808-20261022-215869","content_type":"news","title":"Anvisa预防性查封Libbs亚叶酸钙注射液批次25D0808","summary":"巴西国家卫生监督局对Libbs公司生产的Fauldleuco（亚叶酸钙）注射液批号25D0808实施预防性查封，疑因颗粒物质量偏差。","body":"巴西国家卫生监督局（Anvisa）于周四（10月22日）决定对Libbs Farmacêutica Ltda.公司（CNPJ：61.230.314/0001-75）生产的Fauldleuco（亚叶酸钙）10 MG/ML注射液、CT FA VD TRANS X 30的批号25D0808实施预防性查封，原因是该特定批次产品疑似存在与颗粒物相关的质量偏差。\n\n该药品的适应症为治疗巨幼细胞性贫血，以及结直肠癌化疗的辅助支持。\n\nAnvisa说明，预防性查封是一项临时性预防措施，旨在保护公众健康，在调查和结案所需的检测、检验、分析或其他措施完成之前持续有效。因此，在证明该产品安全性之前，不得使用或销售该批次产品。\n\n相关决议为第4.150/2026号，已刊登于《联邦官方公报》（DOU）。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","政策","公共事件","br-health"],"content_level":"编辑整理","event_type":"公共事件","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-22T17:01:21.364Z","display_date":"2026-10-22","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-interdita-cautelarmente-lote-do-medicamento-fauldleuco","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":[]},"intelligence":{"intel_id":"6ffb4254-2739-4d07-a023-6a8bc16cc925","version":1,"event_type":"风险事件","event_date":"2026-10-22","main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"决定并实施预防性查封的监管机构","type":"regulator","country":"巴西","normalized_name":null},{"name":"Libbs Farmacêutica Ltda.","role":"涉事药品生产商","type":"company","country":"巴西","normalized_name":null},{"name":"Fauldleuco（亚叶酸钙）10 MG/ML注射液 CT FA VD TRANS X 30 批号25D0808","role":"被实施预防性查封的特定批次药品","type":"product","country":"巴西","normalized_name":null},{"name":"第4.150/2026号决议","role":"相关监管决议，已刊登于《联邦官方公报》","type":"policy","country":"巴西","normalized_name":null}],"main_action":"Anvisa对Libbs生产的亚叶酸钙注射液批号25D0808实施预防性查封","key_numbers":[{"unit":"","label":"产品批号","value":"25D0808"},{"unit":"MG/ML","label":"药品规格","value":"10"},{"unit":"","label":"决议编号","value":"4.150/2026"},{"unit":"","label":"公司CNPJ","value":"61.230.314/0001-75"}],"facts":[{"verified":false,"statement":"Anvisa决定对Libbs Farmacêutica Ltda.生产的Fauldleuco（亚叶酸钙）10 MG/ML注射液批号25D0808实施预防性查封。","source_excerpt":null},{"verified":false,"statement":"查封原因为该特定批次产品疑似存在与颗粒物相关的质量偏差。","source_excerpt":null},{"verified":false,"statement":"Anvisa说明预防性查封为临时性预防措施，在调查、检测、分析等完成前持续有效；在证明产品安全性之前不得使用或销售该批次产品。","source_excerpt":null},{"verified":false,"statement":"相关决议为第4.150/2026号，已刊登于《联邦官方公报》（DOU）。","source_excerpt":null},{"verified":false,"statement":"该药品适应症为治疗巨幼细胞性贫血及结直肠癌化疗的辅助支持。","source_excerpt":null},{"verified":false,"statement":"Libbs Farmacêutica Ltda.的CNPJ为61.230.314/0001-75。","source_excerpt":null}],"assessments":[{"statement":"该行动仅针对批号25D0808，现有信息未表明Libbs其他批次或其他产品被查封。","confidence":"medium","basis_fact_index":null},{"statement":"Anvisa采用预防性查封说明监管机构将该疑似颗粒物偏差视为需要先行控制的风险，而非已确认的最终结论。","confidence":"high","basis_fact_index":null},{"statement":"若后续检测确认颗粒物风险，该批次可能面临召回或更严格监管措施。","confidence":"medium","basis_fact_index":null},{"statement":"该事件可能对巴西亚叶酸钙相关供应链和医疗机构用药安排造成短期不确定性。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"system","priority":"high","description":"监测Anvisa及《联邦官方公报》后续更新，确认是否发布召回、解封或检测结论。"},{"target":"user","priority":"high","description":"核查库存、采购和处方中是否涉及批号25D0808，并按监管要求停用或停售。"},{"target":"both","priority":"normal","description":"如涉及跨境贸易，核实该批次是否进入中国或其他市场并评估口岸及合规风险。"}],"affected_audience":["使用亚叶酸钙注射液的患者","医疗机构和处方医生","药品经销商和进口商","Libbs Farmacêutica Ltda.","巴西药品供应链相关方"],"risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":[],"follow_up_needed":true,"follow_up_questions":["Anvisa是否已要求召回，还是仅对涉事批次库存实施查封？","批号25D0808的颗粒物检测结果和调查结论何时公布？","该批次是否出口至中国或其他国家？","Libbs是否已就其他批次开展质量排查？"],"related_topics":["Anvisa","Libbs","亚叶酸钙","Fauldleuco","药品质量偏差","预防性查封","颗粒物污染","巴西药品监管"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-22T17:01:47.088Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-libbs-25d0808-20261022-215869","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-libbs-25d0808-20261022-215869","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-libbs-25d0808-20261022-215869?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-libbs-25d0808-20261022-215869?view=json","last_updated":"2026-10-22T17:01:47.768Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}